Healthtech funding in Q1 2017
European Healthtech startup funding raised during Q1 2017.
In Q1 2017, 77 European Healthtech companies closed 79 funding rounds and raised €406M in equity funding (excluding debt and grants), up 28.1% versus Q1 2016. Debt rounds added €7.0M. UK led by capital raised, and Bpifrance was the most active investor. Data as of 20 Nov 2026.
Equity funding
€406M
+28.1% vs Q1 2016 · excl. debt & grants · +€7.0M debt
Funding rounds
79
+12.9% vs Q1 2016
Companies
77
Top country
UK
Rank among sectors
#4
5.3% of sector funding
Debt financing
€7.0M
1.7% of total
Top-10 round share
58.3%
of disclosed capital
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, Q1 2017 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Jan | €158M | 28 |
| Feb | €62M | 21 |
| Mar | €192M | 30 |
Top countries
by € raisedHealthtech — top countries by capital, Q1 2017 — interactive chart.
Data table
| Healthtech — top countries by capital, Q1 2017 | |
|---|---|
| UK | €110M |
| France | €80M |
| Germany | €64M |
| Israel | €61M |
| Spain | €39M |
| Sweden | €23M |
| Ireland | €15M |
| Netherlands | €10M |
Stage mix
by € raisedHealthtech — stage mix, Q1 2017 — interactive chart.
Data table
| Healthtech — stage mix, Q1 2017 | |
|---|---|
| Series B | €100M |
| Early VC | €82M |
| Series A | €74M |
| Growth/Late | €53M |
| Series D+ | €32M |
| Other | €31M |
| Series C | €26M |
| Seed | €8.1M |
| Debt | €7.0M |
Exits & M&A
7 Acquisition · 1 IPO8 exits · €318M disclosed.
| Zur Rose | IPO | Jan 2017 | €184M |
| Europa Apotheek | Acquisition | Feb 2017 | €126M |
| Evoxx Technologies | Acquisition | Feb 2017 | €7.7M |
Top deals
largest disclosed rounds in Q1 2017| Company | Stage | Date | Amount |
|---|---|---|---|
| Breath Therapeutics | Series A | Mar 2017 | €44M |
| Medlumics | Series B | Mar 2017 | €34M |
| Atlas Genetics | Series D+ | Jan 2017 | €32M |
| Pulmocide | Series B | Mar 2017 | €28M |
| Doctolib | Series C | Jan 2017 | €26M |
| Cambridge Medical Robotics | Other | Mar 2017 | €25M |
| HealthWatch | Growth/Late | Jan 2017 | €18M |
| MediSafe | Series B | Mar 2017 | €13M |
| TxCell | Growth/Late | Feb 2017 | €11M |
| Owlstone Medical | Growth/Late | Jan 2017 | €11M |
| myTomorrows | Growth/Late | Jan 2017 | €10M |
| CellProthera | Early VC | Jan 2017 | €8.3M |
| Amra | Early VC | Jan 2017 | €8.2M |
| Hemarina | Early VC | Mar 2017 | €8.0M |
| Luxendo | Series A | Jan 2017 | €8.0M |
Top investors
most active in Q1 2017, by deal count- Bpifrance5 deals
- Caixa Capital Risc2 deals
- High-Tech Gründerfonds (HTGF)2 deals
- Invitalia Ventures2 deals
- Johnson & Johnson Innovation2 deals
- Octopus Ventures2 deals
- Sofinnova Partners2 deals
- TriVentures2 deals
- 7wire Ventures1 deals
- Accel1 deals